Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
Date:3/5/2009

2008, our management and Board of Directors determined to explore and pursue various restructuring and cost reduction initiatives in order to conserve our liquidity, as well as various financial and strategic transactions that could potentially reduce or eliminate our existing debt obligations and improve our working capital position.

On July 7, 2008, we announced that our Board of Directors had authorized a transaction to create a new subsidiary, Angiotech Pharmaceutical Interventions Inc. ("API"), and that we would contribute certain business assets and intellectual property to API, primarily consisting of business assets of Angiotech other than the intellectual property and royalty revenue related to TAXUS(R) coronary stent systems. In connection with this transaction, we were to receive $200 to $300 million of new financing from new investors to establish API, which financing was targeted to reduce substantial amounts of our existing debt obligations with equivalent amounts of convertible debt bearing interest in additional equity of the newly created subsidiary in kind, as opposed to cash. This transaction, if approved by our shareholders and completed, would have substantially reduced our annual cash pay interest obligations.

On September 22, 2008, we announced that we had postponed the planned shareholder vote regarding the proposed API transaction. As of that date, given the time required for more extended discussions to address concerns of certain of our shareholders and bondholders, and given various other factors impacting our business and cash position (including lower expected revenues derived from BSC), we did not believe we would be able to satisfy the transaction condition with respect to the minimum level of cash and cash equivalents required to be held at the time of the transaction's close.

On September 22, 2008, we also announced that we would pursue various initiatives to reduce operating costs and further focus our busin
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
2. Angiotech Pharmaceuticals announces time change of conference call and webcast
3. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
4. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
5. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. Angiotech wins before the UK House of Lords
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
10. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... (PRWEB) September 17, 2014 The ... committed to lowering the barriers to innovation in ... the appointment of Carmen Nitsche as Executive Director ... to expand its global reach. , Carmen joins ... Vice President, Corporate Development. At Accelrys, she managed ...
(Date:9/16/2014)... , Sept. 16, 2014 This report analyzes ... following Product Segments: Software, Hardware, and Biocontent. The report provides ... , Japan , Europe ... , and Rest of World. Annual estimates and forecasts ... seven-year historic analysis is provided for these markets. Market data ...
(Date:9/16/2014)... --The emerging field of molecular electronics could take ... enabling the construction of tiny circuits from molecular ... would take on the roles currently played by ... of researchers from five Japanese and Taiwanese universities ... small-scale electronics: a molecule called picene. In a ...
(Date:9/16/2014)... 16, 2014 BlueInGreen® , ... efficient method for delivering dissolved gases into liquids, ... as a manufacturer’s representative firm to its ... products for municipal water and wastewater applications in ... H2Flow was founded in 1992 and serves Quebec ...
Breaking Biology Technology:Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23The future face of molecular electronics 2BlueInGreen® Expands into Canada – Signs Representative Agreement with H2Flow Equipment Inc. 2
... and STATE COLLEGE, Pennsylvania, May 9, 2012 ... and SoftGenetics announced today that the two firms ... provide users of 454 Sequencing Systems the broad ... by SoftGenetics NextGENe® software. NextGENe® software ...
... 2012 Phalanx Biotech Group, a global genomic ... of manufacturing and testing for a proprietary targeted ... postnatal detection of microdeletions and microduplications related to ... intellectual delay disorders. Cyto OneArray ® ...
... Nev., May 8, 2012 PDL BioPharma, Inc. (PDL) (NASDAQ: ... the company,s president and chief executive officer, is scheduled to ... http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) Eleventh Annual JMP Securities Research ... Francisco, CA Goldman Sachs 33rd Annual Global ...
Cached Biology Technology:Roche 454 Life Sciences and SoftGenetics Sign Co-Promotion Agreement for Next-Gen Sequencing Software Tools 2Roche 454 Life Sciences and SoftGenetics Sign Co-Promotion Agreement for Next-Gen Sequencing Software Tools 3Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray 2
(Date:9/16/2014)... RALEIGH, N.C. , Sept. 16, 2014  Valencell, ... has been chosen as one of 18 "Showcase Companies" ... technology businesses at the annual CED Tech Venture Conference ... Raleigh Convention Center in Raleigh, ... LeBoeuf will lead a discussion during the "Digital ...
(Date:9/15/2014)... and gut microbes influence processes from digestion to disease ... most biodiverse terrestrial ecosystems on the planet, more is ... the tropics. Smithsonian scientists and colleagues working on Panama,s ... a single tree were home to more than 400 ... tree species contained more than 7,000 different kinds. , ...
(Date:9/15/2014)... Adding a common epilepsy drug to a morphine regimen ... effects. Moreover, the combination can reduce the dosage of ... team of pain researchers at Indiana University. , The ... neuropathic pain, a difficult-to-treat condition often felt in the ... , "There is a huge unmet need for better ...
Breaking Biology News(10 mins):Valencell, Inc. Selected as 'Showcase Company' at CED Tech Venture Conference 2014 2Smithsonian scientists discover tropical tree microbiome in Panama 2IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2
... (BUSM) and Veterans Affairs (VA) Boston Healthcare System have identified ... findings, published online in Molecular Psychiatry , indicate that ... cells from the damaging effects of stress may also be ... reports the first positive results of a genome-wide association study ...
... A top national award for promising research scientists ... assistant professor of biology at Rutgers UniversityCamden. Yakoby ... Science Foundation. The five-year, $686,544 award, which is ... of the project, supports the RutgersCamden researcher,s project "Dynamics ...
... for plants but also for all living organisms. In ... growing shortage of this essential mineral, and the price ... therefore high time to start looking for alternatives. This ... replaced by any other substance. But researchers at the ...
Cached Biology News:BUSM/VA Boston Healthcare System investigators identify new gene linked to PTSD 2Rutgers-Camden genetics researcher receives NSF CAREER Award 2Using wastewater as fertilizer 2Using wastewater as fertilizer 3
... Human CELSR3 CELSR3 is an Orphan-U ... this gene is expressed during development at sites ... rats in brain, spinal cord, dorsal root ganglion, ... B-cell/lung/testis, blood, brain, colon, heart/melanocyte/uterus, lung, nerve, and ...
Smac/DIABLO (CT) - IgG for Western Blotting, Host: Rabbit Family: Smac/DIABLO...
Mouse Amphiregulin MAb (Clone 206220)...
Anti-Digoxigenin-AP, Fab fragments; from sheep...
Biology Products: